Նորվեգիա -
Նորվեգերեն -
Statens legemiddelverk
mitoxantron ebewe 2 mg/ ml
ebewe pharma ges.m.b.h nfg. kg - mitoksantronhydroklorid - konsentrat til infusjonsvæske, oppløsning - 2 mg/ ml
Նորվեգիա -
Նորվեգերեն -
Statens legemiddelverk
novantrone 2 mg/ ml
viatris as - mitoksantronhydroklorid - konsentrat til infusjonsvæske, oppløsning - 2 mg/ ml
Եվրոպական Միություն -
Նորվեգերեն -
EMA (European Medicines Agency)
zeposia
bristol-myers squibb pharma eeig - ozanimod hydrochloride - multiple sclerosis, relapsing-remitting; colitis, ulcerative - immunsuppressive - multiple sclerosiszeposia is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis (rrms) with active disease as defined by clinical or imaging features. ulcerative colitiszeposia is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis (uc) who have had an inadequate response, lost response, or were intolerant to either conventional therapy or a biologic agent.
Եվրոպական Միություն -
Նորվեգերեն -
EMA (European Medicines Agency)
nexgard combo
boehringer ingelheim vetmedica gmbh - eprinomectin, esafoxolaner, praziquantel - eprinomectin, combinations, , avermectins, antiparasitic products, insecticides and repellents - katter - for cats with, or at risk from mixed infections by cestodes, nematodes and ectoparasites. veterinærpreparatet er kun indisert når alle tre gruppene er målrettet på samme tid.
Եվրոպական Միություն -
Նորվեգերեն -
EMA (European Medicines Agency)
tyruko
sandoz gmbh - natalizumab - multiple sclerosis, relapsing-remitting; multiple sclerosis - immunsuppressive - tyruko is indicated as single disease modifying therapy in adults with highly active relapsing remitting multiple sclerosis (rrms) for the following patient groups: patients with highly active disease despite a full and adequate course of treatment with at least one disease modifying therapy (dmt) (for exceptions and information about washout periods see sections 4. 4 og 5. 1), or, patients with rapidly evolving severe rrms defined by 2 or more disabling relapses in one year, and with 1 or more gadolinium enhancing lesions on brain magnetic resonance imaging (mri) or a significant increase in t2 lesion load as compared to a previous recent mri.